Top

BMC Cancer

Published in:

Open Access 01-12-2018 | Research article

Neuroendocrine carcinoma of the cervix: a systematic review of the literature

Authors: Clemens B. Tempfer, Iris Tischoff, Askin Dogan, Ziad Hilal, Beate Schultheis, Peter Kern, Günther A. Rezniczek

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

Neuroendocrine carcinoma of the cervix (NECC) is a rare variant of cervical cancer. The prognosis of women with NECC is poor and there is no standardized therapy for this type of malignancy based on controlled trials.

Methods

We performed a systematic literature search of the databases PubMed and Cochrane Central Register of Controlled Trials to identify clinical trials describing the management and outcome of women with NECC.

Results

Three thousand five hundred thirty-eight cases of NECC in 112 studies were identified. The pooled proportion of NECC among women with cervical cancer was 2303/163470 (1.41%). Small cell NECC, large cell NECC, and other histological subtypes were identified in 80.4, 12.0, and 7.6% of cases, respectively. Early and late stage disease presentation were evenly distributed with 1463 (50.6%) and 1428 (49.4%) cases, respectively. Tumors expressed synaptophysin (424/538 cases; 79%), neuron-specific enolase (196/285 cases; 69%), chromogranin (323/486 cases; 66%), and CD56 (162/267; 61%). The most common primary treatment was radical surgery combined with chemotherapy either as neoadjuvant or adjuvant chemotherapy, described in 42/48 studies. Radiotherapy-based primary treatment schemes in the form of radiotherapy, radiochemotherapy, or radiotherapy with concomitant or followed by chemotherapy were also commonly used (15/48 studies). There is no standard chemotherapy regimen for NECC, but cisplatin/carboplatin and etoposide (EP) was the most commonly used treatment scheme (24/40 studies). Overall, the prognosis of women with NECC was poor with a mean recurrence-free survival of 16 months and a mean overall survival of 40 months. Immune checkpoint inhibitors and targeted agents were reported as being active in three case reports.

Conclusion

NECC is a rare variant of cervical cancer with a poor prognosis. Multimodality treatment with radical surgery and neoadjuvant/adjuvant chemotherapy with cisplatin and etoposide with or without radiotherapy is the mainstay of treatment for early stage disease while chemotherapy with cisplatin and etoposide or topotecan, paclitaxel, and bevacizumab is appropriate for women with locally advanced or recurrent NECC. Immune checkpoint inhibitors may be beneficial, but controlled evidence for their efficacy is lacking.

Available only for authorised users

Gadducci A, Carinelli S, Aletti G. Neuroendrocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists. Gynecol Oncol. 2017;144:637–46. https://doi.org/10.1016/j.ygyno.2016.12.003.PubMedCrossRef

Kim JY, Hong SM, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11–6.

Guadagno E, de RG, de Del Basso Caro M. Neuroendocrine tumours in rare sites: differences in nomenclature and diagnostics-a rare and ubiquitous histotype. J Clin Pathol. 2016;69:563–74. https://doi.org/10.1136/jclinpath-2015-203551.PubMedCrossRef

Burzawa J, Gonzales N, Frumovitz M. Challenges in the diagnosis and management of cervical neuroendocrine carcinoma. Expert Rev Anticancer Ther. 2015;15:805–10. https://doi.org/10.1586/14737140.2015.1047767.PubMedCrossRef

Lax SF, Horn LC, Löning T. Categorization of uterine cervix tumors: What's new in the 2014 WHO classification. Pathologe. 2016;37(6):573–84.

Grande E, Capdevila J, Castellano D, Teulé A, Durán I, Fuster J, et al. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish task force Group for Neuroendocrine Tumors (GETNE). Ann Oncol. 2015;26:1987–93. https://doi.org/10.1093/annonc/mdv252.PubMedCrossRef

Chen CA, Wu CC, Juang GT, Wang JF, Chen TM, Hsieh CY. Serum neuron-specific enolase levels in patients with small cell carcinoma of the uterine cervix. J Formos Med Assoc. 1994;93:81–3.PubMed

Wang HL, Lu DW. Detection of human papillomavirus DNA and expression of p16, Rb, and p53 proteins in small cell carcinomas of the uterine cervix. Am J Surg Pathol. 2004;28:901–8.PubMedCrossRef

Castle PE, Pierz A, Stoler MH. A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix. Gynecol Oncol. 2018;148:422–9. https://doi.org/10.1016/j.ygyno.2017.12.001.PubMedCrossRef

10.

Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: a Society of Gynecologic Oncology (SGO) clinical document. Gynecol Oncol. 2011;122:190–8. https://doi.org/10.1016/j.ygyno.2011.04.011.PubMedCrossRef

11.

Satoh T, Takei Y, Treilleux I, Devouassoux-Shisheboran M, Ledermann J, Viswanathan AN, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for small cell carcinoma of the cervix. Int J Gynecol Cancer. 2014;24:S102–8. https://doi.org/10.1097/IGC.0000000000000262.PubMedCrossRef

12.

Yin ZM, Yu AJ, Wu MJ, Fang J, Liu LF, Zhu JQ, Yu H. Effects and toxicity of neoadjuvant chemotherapy preoperative followed by adjuvant chemoradiation in small cell neurdendocrine cervical carcinoma. Eur J Gynaecol Oncol. 2015;36:326–9.PubMed

13.

Nasu K, Hirakawa T, Okamoto M, Nishida M, Kiyoshima C, Matsumoto H, et al. Advanced small cell carcinoma of the uterine cervix treated by neoadjuvant chemotherapy with irinotecan and cisplatin followed by radical surgery. Rare Tumors. 2011;3:e6. https://doi.org/10.4081/rt.2011.e6.PubMedPubMedCentralCrossRef

14.

Hoskins PJ, Swenerton KD, Pike JA, Lim P, Aquino-Parsons C, Wong F, Lee N. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol. 2003;21:3495–501. https://doi.org/10.1200/JCO.2003.01.501.PubMedCrossRef

15.

Bermúdez A, Vighi S, García A, Sardi J. Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge. Gynecol Oncol. 2001;82:32–9. https://doi.org/10.1006/gyno.2001.6201.PubMedCrossRef

16.

Albores-Saavedra J, Gersell D, Gilks CB, Henson DE, Lindberg G, Santiago H, et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med. 1997;121:34–9.PubMed

17.

Abdallah R, Bush SH, Chon HS, Apte SM, Wenham RM, Shahzad MMK. Therapeutic dilemma: prognostic factors and outcome for neuroendocrine tumors of the cervix. Int J Gynecol Cancer. 2016;26:553–60. https://doi.org/10.1097/IGC.0000000000000631.PubMedCrossRef

18.

Abeler VM, Holm R, Nesland JM, Kjørstad KE. Small cell carcinoma of the cervix. A clinicopathologic study of 26 patients. Cancer. 1994;73:672–7.PubMedCrossRef

19.

Abulafia O, Sherer DM. Adjuvant chemotherapy in stage IB neuroendocrine small cell carcinoma of the cervix. Acta Obstet Gynecol Scand. 1995;74:740–4.PubMedCrossRef

20.

Agarwal S, Schmeler KM, Ramirez PT, Sun CC, Nick A, Dos Reis R, et al. Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histological subtypes. Int J Gynecol Cancer. 2011;21:123–7. https://doi.org/10.1097/IGC.0b013e3181ffccc1.PubMedPubMedCentralCrossRef

21.

Albores-Saavedra J, Martinez-Benitez B, Luevano E. Small cell carcinomas and large cell neuroendocrine carcinomas of the endometrium and cervix: polypoid tumors and those arising in polyps may have a favorable prognosis. Int J Gynecol Pathol. 2008;27:333–9. https://doi.org/10.1097/PGP.0b013e31815de006.PubMedCrossRef

22.

Alphandery C, Dagrada G, Frattini M, Perrone F, Pilotti S. Neuroendocrine small cell carcinoma of the cervix associated with endocervical adenocarcinoma: a case report. Acta Cytol. 2007;51:589–93.PubMedCrossRef

23.

Ambros RA, Park JS, Shah KV, Kurman RJ. Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18. Mod Pathol. 1991;4:586–93.PubMed

24.

Asensio N, Luis A, Costa I, Oliveira J, Vaz F. Meningeal carcinomatosis and uterine carcinoma: three different clinical settings and review of the literature. Int J Gynecol Cancer. 2009;19:168–72. https://doi.org/10.1111/IGC.0b013e31819a1e1a.PubMedCrossRef

25.

Balega J, Ulbright TM, Look KY. Coexistence of metastatic neuroendocrine carcinoma of the uterine cervix with human immunodeficiency virus infection. Int J Gynecol Cancer. 2001;11:334–7.PubMedCrossRef

26.

Baykal C, Al A, Tulunay G, Bulbul D, Güler G, Ozer S, Küçükali T. High-grade neuroendocrine carcinoma of the cervix. A case report. Gynecol Obstet Investig. 2005;59:207–11. https://doi.org/10.1159/000084259. CrossRef

27.

Bifulco G, Mandato VD, Giampaolino P, Piccoli R, Insabato L, de Rosa N, Nappi C. Small cell neuroendocrine cervical carcinoma with 1-year follow-up: case report and review. Anticancer Res. 2009;29:477–84.PubMed

28.

Brown KR, Leitao MM. Cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with neuroendocrine tumor of the cervix: a case report and review of the literature. Eur J Gynaecol Oncol. 2010;31:107–8.PubMed

29.

Cavalcanti MS, Schultheis AM, Ho C, Wang L, DeLair DF, Weigelt B, et al. Mixed mesonephric adenocarcinoma and high-grade neuroendocrine carcinoma of the uterine cervix: case description of a previously unreported entity with insights into its molecular pathogenesis. Int J Gynecol Pathol. 2017;36:76–89. https://doi.org/10.1097/PGP.0000000000000306.PubMedPubMedCentralCrossRef

30.

Cetiner H, Kir G, Akoz I, Gurbuz A, Karateke A. Large-cell neuroendocrine carcinoma of the cervix associated with cervical-type invasive adenocarcinoma: a report of case and discussion of histogenesis. Int J Gynecol Cancer. 2006;16:438–42. https://doi.org/10.1111/j.1525-1438.2006.00194.x.PubMedCrossRef

31.

Chan JK, Loizzi V, Burger RA, Rutgers J, Monk BJ. Prognostic factors in neuroendocrine small cell cervical carcinoma: A multivariate analysis. Cancer. 2003;97:568–74. https://doi.org/10.1002/cncr.11086.PubMedCrossRef

32.

Chatterjee S, Chakravorty S, Kapoor P, Chattopadhyay D. Small cell neuroendocrine carcinoma of cervix--a case report. Indian J Pathol Microbiol. 2005;48:410–2.PubMed

33.

Chavez-Blanco A, Taja-Chayeb L, Cetina L, Chanona-Vilchis G, Trejo-Becerril C, Perez-Cardenas E, et al. Neuroendocrine marker expression in cervical carcinomas of non-small cell type. Int J Gynecol Pathol. 2002;21:368–74.PubMedCrossRef

34.

Cho SY, Choi M, Ban H-J, Lee CH, Park S, Kim H, et al. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing. Oncotarget. 2017;8:8095–104. https://doi.org/10.18632/oncotarget.14098.PubMedCrossRef

35.

Chun K-C, Kim D-Y, Kim J-H, Kim Y-M, Kim Y-T, Nam J-H. Neoadjuvant chemotherapy with paclitaxel plus platinum followed by radical surgery in early cervical cancer during pregnancy: three case reports. Jpn J Clin Oncol. 2010;40:694–8. https://doi.org/10.1093/jjco/hyq039.PubMedCrossRef

36.

Chung W-K, Yang J-H, Chang S-E, Lee M-W, Choi J-H, Moon K-C, Koh J-K. A case of cutaneous metastasis of small-cell neuroendocrine carcinoma of the uterine cervix. Am J Dermatopathol. 2008;30:636–8. https://doi.org/10.1097/DAD.0b013e31817e6f27.PubMedCrossRef

37.

Cohen JG, Kapp DS, Shin JY, Urban R, Sherman AE, L-m C, et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol. 2010;203:347.e1–6. https://doi.org/10.1016/j.ajog.2010.04.019.CrossRef

38.

Collinet P, Lanvin D, Declerck D, Chevalier-Place A, Leblanc E, Querleu D. Neuroendocrine tumors of the uterine cervix. Clinicopathologic study of five patients. Eur J Obstet Gynecol Reprod Biol. 2000;91:51–7.PubMedCrossRef

39.

Conner MG, Richter H, Moran CA, Hameed A, Albores-Saavedra J. Small cell carcinoma of the cervix: a clinicopathologic and immunohistochemical study of 23 cases. Ann Diagn Pathol. 2002;6:345–8. https://doi.org/10.1053/adpa.2002.36661.PubMedCrossRef

40.

Cui S, Lespinasse P, Cracchiolo B, Sama J, Kreitzer MS, Heller DS. Large cell neuroendocrine carcinoma of the cervix associated with adenocarcinoma in situ: evidence of a common origin. Int J Gynecol Pathol. 2001;20:311–2.PubMedCrossRef

41.

Damian A, Lago G, Rossi S, Alonso O, Engler H. Early detection of bone metastasis in small cell neuroendocrine carcinoma of the cervix by 68Ga-DOTATATE PET/CT imaging. Clin Nucl Med. 2017;42:216–7. https://doi.org/10.1097/RLU.0000000000001498.PubMedCrossRef

42.

Delaloge S, Pautier P, Kerbrat P, Castaigne D, Haie-Meder C, Duvillard P, et al. Neuroendocrine small cell carcinoma of the uterine cervix: what disease? What treatment? Report of ten cases and a review of the literature. Clin Oncol (R Coll Radiol). 2000;12:357–62.CrossRef

43.

Dikmen Y, Kazandi M, Zekioglu O, Ozsaran A, Terek MC, Erhan Y. Large cell neuroendocrine carcinoma of the uterine cervix: a report of a case and review of the literature. Arch Gynecol Obstet. 2004;270:185–8. https://doi.org/10.1007/s00404-003-0482-0.PubMedCrossRef

44.

Donati P, Paolino G, Donati M, Panetta C. Adenocarcinoma of the cervix associated with a neuroendocrine small cell carcinoma of the cervix in the spectrum of Muir-Torre syndrome. Eur J Gynaecol Oncol. 2015;36:213–5.PubMed

45.

Duan X, Ban X, Zhang X, Hu H, Li G, Wang D, et al. MR imaging features and staging of neuroendocrine carcinomas of the uterine cervix with pathological correlations. Eur Radiol. 2016;26:4293–302. https://doi.org/10.1007/s00330-016-4327-1.PubMedCrossRef

46.

Emmett M, Gildea C, Nordin A, Hirschowitz L, Poole J. Variations in treatment of cervical Cancer according to tumor morphology-population-based cohort analysis of English National Cancer Registration Data. Int J Gynecol Cancer. 2017;27:138–46. https://doi.org/10.1097/IGC.0000000000000859.PubMedCrossRef

47.

Frumovitz M, Burzawa JK, Byers LA, Lyons YA, Ramalingam P, Coleman RL, Brown J. Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. Gynecol Oncol. 2016;141:588–91. https://doi.org/10.1016/j.ygyno.2016.04.001.PubMedPubMedCentralCrossRef

48.

Ganesan R, Hirschowitz L, Dawson P, Askew S, Pearmain P, Jones PW, et al. Neuroendocrine carcinoma of the cervix: review of a series of cases and correlation with outcome. Int J Surg Pathol. 2016;24(6):490. https://doi.org/10.1177/1066896916643385.PubMedCrossRef

49.

Gersell DJ, Mazoujian G, Mutch DG, Rudloff MA. Small-cell undifferentiated carcinoma of the cervix. A clinicopathologic, ultrastructural, and immunocytochemical study of 15 cases. Am J Surg Pathol. 1988;12:684–98.PubMedCrossRef

50.

Gilks CB, Young RH, Gersell DJ, Clement PB. Large cell neuroendocrine corrected carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. Am J Surg Pathol. 1997;21:905–14.PubMedCrossRef

51.

Grayson W, Rhemtula HA, Taylor LF, Allard U, Tiltman AJ. Detection of human papillomavirus in large cell neuroendocrine carcinoma of the uterine cervix: a study of 12 cases. J Clin Pathol. 2002;55:108–14.PubMedPubMedCentralCrossRef

52.

Gressner O, Sauerbruch T. Secondary small cell neuroendocrine carcinoma of the cervix after radiotherapy for cervical squamous cell carcinoma. Int J Gynaecol Obstet. 2007;99:138. https://doi.org/10.1016/j.ijgo.2007.05.027.PubMedCrossRef

53.

Hao H, Itoyama M, Tsubamoto H, Tsujimoto M, Hirota S. Large cell neuroendocrine carcinoma of the cervix associated with intestinal variant invasive mucinous adenocarcinoma. Pathol Int. 2011;61:55–7. https://doi.org/10.1111/j.1440-1827.2010.02606.x.PubMedCrossRef

54.

Hara H, Ishii E, Hondo T, Nakagawa M, Teramoto K, Oyama T. Cytological features of atypical carcinoid combined with adenocarcinoma of the uterine cervix. Diagn Cytopathol. 2012;40(8):724. https://doi.org/10.1002/dc.21657.PubMedCrossRef

55.

Herrington CS, Graham D, Southern SA, Bramdev A, Chetty R. Loss of retinoblastoma protein expression is frequent in small cell neuroendocrine carcinoma of the cervix and is unrelated to HPV type. Hum Pathol. 1999;30:906–10.PubMedCrossRef

56.

Horn L-C, Hentschel B, Bilek K, Richter CE, Einenkel J, Leo C. Mixed small cell carcinomas of the uterine cervix: prognostic impact of focal neuroendocrine differentiation but not of Ki-67 labeling index. Ann Diagn Pathol. 2006;10(3):140. https://doi.org/10.1016/j.anndiagpath.2005.07.019.PubMedCrossRef

57.

Horn L-C, Lindner K, Szepankiewicz G, Edelmann J, Hentschel B, Tannapfel A, et al. p16, p14, p53, and cyclin D1 expression and HPV analysis in small cell carcinomas of the uterine cervix. Int J Gynecol Pathol. 2006;25:182–6. https://doi.org/10.1097/01.pgp.0000185406.85685.df.PubMedCrossRef

58.

Hsieh T-C, Wu Y-C, Sun S-S, Yang C-F, Yen K-Y, Liang J-A, Kao C-H. Rare breast and adrenal gland metastases from small-cell neuroendocrine carcinoma of uterine cervix. Clin Nucl Med. 2012;37(3):280. https://doi.org/10.1097/RLU.0b013e31823ea6c4.PubMedCrossRef

59.

Intaraphet S, Kasatpibal N, Siriaunkgul S, Sogaard M, Patumanond J, Khunamornpong S, et al. Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma. Asian Pac J Cancer Prev. 2013;14:5355–60.PubMedCrossRef

60.

Ishida GM, Kato N, Hayasaka T, Saito M, Kobayashi H, Katayama Y, et al. Small cell neuroendocrine carcinomas of the uterine cervix: a histological, immunohistochemical, and molecular genetic study. Int J Gynecol Pathol. 2004;23:366–72.PubMedCrossRef

61.

Kajiwara H, Hirabayashi K, Miyazawa M, Nakamura N, Hirasawa T, Muramatsu T, et al. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine carcinoma of uterine cervix. Arch Gynecol Obstet. 2009;279:521–5. https://doi.org/10.1007/s00404-008-0760-y.PubMedCrossRef

62.

Kasamatsu T, Sasajima Y, Onda T, Sawada M, Kato T, Tanikawa M. Surgical treatment for neuroendocrine carcinoma of the uterine cervix. Int J Gynaecol Obstet. 2007;99:225–8. https://doi.org/10.1016/j.ijgo.2007.06.051.PubMedCrossRef

63.

Kim DY, Yun HJ, Lee YS, Lee HN, Kim CJ. Small cell neuroendocrine carcinoma of the uterine cervix presenting with syndrome of inappropriate antidiuretic hormone secretion. Obstet Gynecol Sci. 2013;56:420–5. https://doi.org/10.5468/ogs.2013.56.6.420.PubMedPubMedCentralCrossRef

64.

Ko M-L, Jeng C-J, Huang S-H, Shen J, Chen S-C, Tzeng C-R. Large cell neuroendocrine carcinoma of the uterine cervix associated with adenocarcinoma. Taiwan J Obstet Gynecol. 2007;46:68–70. https://doi.org/10.1016/S1028-4559(08)60111-4.PubMedCrossRef

65.

Koch CA, Azumi N, Furlong MA, Jha RC, Kehoe TE, Trowbridge CH, et al. Carcinoid syndrome caused by an atypical carcinoid of the uterine cervix. J Clin Endocrinol Metab. 1999;84:4209–13. https://doi.org/10.1210/jcem.84.11.6126.PubMedCrossRef

66.

Komiyama S, Nishio E, Torii Y, Kawamura K, Oe S, Kato R, et al. A case of primary uterine cervical neuroendocrine tumor with meningeal carcinomatosis confirmed by diagnostic imaging and autopsy. Int J Clin Oncol. 2011;16:581–6. https://doi.org/10.1007/s10147-010-0155-5.PubMedCrossRef

67.

Kuji S, Watanabe R, Sato Y, Iwata T, Hirashima Y, Takekuma M, et al. A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: analysis of 37 cases. Gynecol Oncol. 2017;144:384–90. https://doi.org/10.1016/j.ygyno.2016.11.020.PubMedCrossRef

68.

Kumar S, Nair S, Alexander M. Carcinomatous meningitis occurring prior to a diagnosis of large cell neuroendocrine carcinoma of the uterine cervix. J Postgrad Med. 2004;50:311–2.PubMed

69.

Kuroda N, Wada Y, Inoue K, Ohara M, Mizuno K, Toi M, et al. Smear cytology findings of large cell neuroendocrine carcinoma of the uterine cervix. Diagn Cytopathol. 2013;41:636–9. https://doi.org/10.1002/dc.21834.PubMedCrossRef

70.

Lan-Fang L, Hai-Yan S, Zuo-Ming Y, Jian-Qing Z, Ya-Qing C. Small cell neuroendocrine carcinoma of the cervix: analysis of the prognosis and role of radiation therapy for 43 cases. Eur J Gynaecol Oncol. 2012;33:68–73.PubMed

71.

Lee J-M, Lee K-B, Nam J-H, Ryu S-Y, Bae D-S, Park J-T, et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol. 2008;19:321–6. https://doi.org/10.1093/annonc/mdm465.PubMedCrossRef

72.

Lee SW, Nam J-H, Kim D-Y, Kim J-H, Kim K-R, Kim Y-M, Kim Y-T. Unfavorable prognosis of small cell neuroendocrine carcinoma of the uterine cervix: a retrospective matched case-control study. Int J Gynecol Cancer. 2010;20:411–6. https://doi.org/10.1111/IGC.0b013e3181ce427b.PubMedCrossRef

73.

Lee S-W, Lim K-T, Bae DS, Park SY, Kim YT, Kim K-R, Nam J-H. A multicenter study of the importance of systemic chemotherapy for patients with small-cell neuroendocrine carcinoma of the uterine cervix. Gynecol Obstet Investig. 2015;79:172–8. https://doi.org/10.1159/000367920. CrossRef

74.

Lee W-J, Lee D-W, Lee M-W, Choi J-H, Moon K-C, Koh J-K. Multiple cutaneous metastases of neuroendocrine carcinoma derived from the uterine cervix. J Eur Acad Dermatol Venereol. 2009;23:494–6. https://doi.org/10.1111/j.1468-3083.2008.02955.x.PubMedCrossRef

75.

Lenczewski A, Terlikowski S, Sulkowska M, Famulski W, Kisielewski W, Kulikowski M. Small cell carcinoma of the uterine cervix--an uncommon variant of cervical cancer with neuroendocrine features. Folia Histochem Cytobiol. 2001;39(Suppl 2):89–90.PubMed

76.

Li S, Zhu H. Twelve cases of neuroendocrine carcinomas of the uterine cervix: cytology, histopathology and discussion of their histogenesis. Acta Cytol. 2013;57:54–60. https://doi.org/10.1159/000342516.PubMedCrossRef

77.

Li WWH, Yau TN, Leung CWL, Pong WM, Chan MYM. Large-cell neuroendocrine carcinoma of the uterine cervix complicating pregnancy. Hong Kong Med J. 2009;15:69–72.PubMed

78.

Lin Y, Lin WY, Liang JA, Lu YY, Wang HY, Tsai SC, Kao CH. Opportunities for 2-(18)F fluoro-2-deoxy-D-glucose PET/CT in cervical-vaginal neuroendocrine carcinoma: Case series and literature review. Korean J Radiol. 2012;13:760–70. https://doi.org/10.3348/kjr.2012.13.6.760.PubMedPubMedCentralCrossRef

79.

Majhi U, Murhekar K, Sundersingh S, Srinivasan V. Basaloid squamous cell carcinoma of cervix showing neuroendocrine differentiation. J Cancer Res Ther. 2015;11:492–3. https://doi.org/10.4103/0973-1482.146114.PubMedCrossRef

80.

Mannion C, Park WS, Man YG, Zhuang Z, Albores-Saavedra J, Tavassoli FA. Endocrine tumors of the cervix: morphologic assessment, expression of human papillomavirus, and evaluation for loss of heterozygosity on 1p,3p, 11q, and 17p. Cancer. 1998;83:1391–400.PubMedCrossRef

81.

Markopoulos MC, Lagadas AA, Alexandrou P, Giannakopoulos KC, Polyzos A. Prolonged disease free survival with aggressive adjuvant chemotherapy in a case of large cell neuroendocrine carcinoma of the uterine cervix. J BUON. 2009;14:322–3.PubMed

82.

Marongiu A, Salvati M, D'Elia A, Arcella A, Giangaspero F, Esposito V. Single brain metastases from cervical carcinoma: report of two cases and critical review of the literature. Neurol Sci. 2012;33:937–40. https://doi.org/10.1007/s10072-011-0861-4.PubMedCrossRef

83.

Marshall L-J, Sutton CD, White SA, Mackay H, Dennison AR. Syndrome X induced by carcinoid syndrome secondary to a cervical neuroendocrine primary tumour. ANZ J Surg. 2002;72:372–4.PubMedCrossRef

84.

McCluggage WG, Kennedy K, Busam KJ. An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms that are commonly TTF1 positive and which may express CK20 and P63. Am J Surg Pathol. 2010;34:525–32. https://doi.org/10.1097/PAS.0b013e3181d1d457.PubMedCrossRef

85.

McGarry RC, Smith C, Seemayer TA. Treatment resistant small cell carcinoma of the cervix. Oncology. 1999;57:293–6. https://doi.org/10.1159/000012063.PubMedCrossRef

86.

Nagao S, Miwa M, Maeda N, Kogiku A, Yamamoto K, Morimoto A, et al. Clinical features of neuroendocrine carcinoma of the uterine cervix: a single-institution retrospective review. Int J Gynecol Cancer. 2015;25:1300–5. https://doi.org/10.1097/IGC.0000000000000495.PubMedCrossRef

87.

Nakata SI, Yamamoto K, Kobayashi Y, Maeda K, Tsuda H, Deguchi M, et al. Excellent results of radiotherapy for neuroendocrine carcinoma of the uterine cervix. Oncol Rep. 2001;8:777–9.PubMed

88.

Niwa K, Nonaka-Shibata M, Satoh E, Hirose Y. Cervical large cell neuroendocrine carcinoma with cytologic presentation: a case report. Acta Cytol. 2010;54:977–80.PubMed

89.

Ohwada M, Wada T, Saga Y, Tsunoda S, Jobo T, Kuramoto H, et al. C-kit overexpression in neuroendocrine small cell carcinoma of the uterine cervix. Eur J Gynaecol Oncol. 2006;27:53–5.PubMed

90.

Perrin L, Bell J, Ward B. Small cell carcinoma of the cervix of neuroendocrine origin causing obstructed labour. Aust N Z J Obstet Gynaecol. 1996;36:85–7.PubMedCrossRef

91.

Powell JL, McKinney CD. Large cell neuroendocrine tumor of the cervix and human papillomavirus 16: a case report. J Low Genit Tract Dis. 2008;12:242–4. https://doi.org/10.1097/LGT.0b013e3181641b4f.PubMedCrossRef

92.

Puig F, Rodrigo C, Muñoz G, Lanzón R. Small cell neuroendocrine carcinoma of the cervix: report of two cases. Eur J Gynaecol Oncol. 2009;30:321–2.PubMed

93.

Pyeon SY, Park JY, Ulak R, Seol HJ, Lee JM. Isolated brain metastasis from uterine cervical cancer: a case report and review of literature. Eur J Gynaecol Oncol. 2015;36:602–4.PubMed

94.

Ramalingam P, Malpica A, Deavers MT. Mixed endocervical adenocarcinoma and high-grade neuroendocrine carcinoma of the cervix with ovarian metastasis of the former component: a report of 2 cases. Int J Gynecol Pathol. 2012;31:490–6. https://doi.org/10.1097/PGP.0b013e31824735a5.PubMedCrossRef

95.

Rashed MM, Bekele A. Neuroendocrine differentiation in a case of cervical cancer. Pan Afr Med J. 2010;6:4.PubMed

96.

Rekhi B, Patil B, Deodhar KK, Maheshwari A, A Kerkar R, Gupta S, et al. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India. Ann Diagn Pathol. 2013;17:1–9. https://doi.org/10.1016/j.anndiagpath.2012.01.009.PubMedCrossRef

97.

Rhemtula H, Grayson W, van Iddekinge B, Tiltman A. Large-cell neuroendocrine carcinoma of the uterine cervix--a clinicopathological study of five cases. S Afr Med J. 2001;91:525–8.PubMed

98.

Rhiem K, Possover M, Gossmann A, Drebber K, Mallmann P, Ulrich U. “Occult” neuroendocrine component and rare metastatic pattern in cervical cancer: report of a case and brief review of the literature. Eur J Gynaecol Oncol. 2007;28:139–41.PubMed

99.

Ribeiro-Silva A, Novello-Vilar A, Cunha-Mercante AM, de Angelo Andrade LAL. Malignant mixed Mullerian tumor of the uterine cervix with neuroendocrine differentiation. Int J Gynecol Cancer. 2002;12:223–7.PubMedCrossRef

100.

Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy. Brachytherapy. 2016;15:845–50. https://doi.org/10.1016/j.brachy.2016.08.007.PubMedCrossRef

101.

Sato Y, Shimamoto T, Amada S, Asada Y, Hayashi T. Large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathological study of six cases. Int J Gynecol Pathol. 2003;22:226–30. https://doi.org/10.1097/01.PGP.0000071046.12278.D1.PubMedCrossRef

102.

Sharabi A, Kim SS, Kato S, Sanders PD, Patel SP, Sanghvi P, et al. Exceptional response to Nivolumab and stereotactic body radiation therapy (SBRT) in neuroendocrine cervical carcinoma with high tumor mutational burden: management considerations from the center for personalized Cancer therapy at UC san Diego Moores Cancer center. Oncologist. 2017;22:631–7. https://doi.org/10.1634/theoncologist.2016-0517.PubMedPubMedCentralCrossRef

103.

Sheets EE, Berman ML, Hrountas CK, Liao SY, DiSaia PJ. Surgically treated, early-stage neuroendocrine small-cell cervical carcinoma. Obstet Gynecol. 1988;71:10–4.PubMed

104.

Silva-Meléndez PE, Escobar PF, Héctor S, Gutiérrez S, Rodríguez M. Small cell carcinoma of the uterine cervix: a case report and literature review. Bol Asoc Med P R. 2015;107:55–7.PubMed

105.

Singh S, Redline R, Resnick KE. Fertility-sparing management of a stage IB1 small cell neuroendocrine cervical carcinoma with radical abdominal trachelectomy and adjuvant chemotherapy. Gynecol Oncol Rep. 2015;13:5–7. https://doi.org/10.1016/j.gore.2015.04.004.PubMedPubMedCentralCrossRef

106.

Siriaunkgul S, Utaipat U, Suwiwat S, Settakorn J, Sukpan K, Srisomboon J, Khunamornpong S. Prognostic value of HPV18 DNA viral load in patients with early-stage neuroendocrine carcinoma of the uterine cervix. Asian Pac J Cancer Prev. 2012;13:3281–5.PubMedCrossRef

107.

Sisti G, Buccoliero AM, Novelli L, Sansovini M, Severi S, Pieralli A, et al. A case of metachronous double primary neuroendocrine cancer in pancreas/ileum and uterine cervix. Ups J Med Sci. 2012;117:453–6. https://doi.org/10.3109/03009734.2012.707254.PubMedPubMedCentralCrossRef

108.

Sitthinamsuwan P, Angkathunyakul N, Chuangsuwanich T, Inthasorn P. Neuroendocrine carcinomas of the uterine cervix: a clinicopathological study. J Med Assoc Thail. 2013;96:83–90.

109.

Sodsanrat K, Saeaib N, Liabsuetrakul T. Comparison of clinical manifestations and survival outcomes between neuroendocrine tumor and squamous cell carcinoma of the uterine cervix: results from a tertiary Center in Southern Thailand. J Med Assoc Thail. 2015;98:725–33.

110.

Straughn JM, Richter HE, Conner MG, Meleth S, Barnes MN. Predictors of outcome in small cell carcinoma of the cervix--a case series. Gynecol Oncol. 2001;83:216–20. https://doi.org/10.1006/gyno.2001.6385.PubMedCrossRef

111.

Strinić T, Tomić S, Pejković L, Eterović D, Forko JI, Karelović DA. Cure from the small cell neuroendocrine carcinoma of the uterine cervix following conventional surgery. Zentralbl Gynakol. 2000;122:387–9.PubMed

112.

Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Int J Gynecol Cancer. 2005;15:646–56. https://doi.org/10.1111/j.1525-1438.2005.00121.x.PubMedCrossRef

113.

Tangjitgamol S, Manusirivithaya S, Choomchuay N, Leelahakorn S, Thawaramara T, Pataradool K, Suekwatana P. Paclitaxel and carboplatin for large cell neuroendocrine carcinoma of the uterine cervix. J Obstet Gynaecol Res. 2007;33:218–24. https://doi.org/10.1111/j.1447-0756.2007.00509.x.PubMedCrossRef

114.

Teefey P, Orr B, Vogt M, Roberts W. Neuroendocrine carcinoma of the cervix during pregnancy: a case report. Gynecol Oncol Case Rep. 2012;2:73–4. https://doi.org/10.1016/j.gynor.2012.03.003.PubMedPubMedCentralCrossRef

115.

Toki T, Katayama Y, Motoyama T. Small-cell neuroendocrine carcinoma of the uterine cervix associated with micro-invasive squamous cell carcinoma and adenocarcinoma in situ. Pathol Int. 1996;46:520–5.PubMedCrossRef

116.

Trinh XB, Bogers JJ, van Marck EA, Tjalma WAA. Treatment policy of neuroendocrine small cell cancer of the cervix. Eur J Gynaecol Oncol. 2004;25:40–4.PubMed

117.

Tsunoda S, Jobo T, Arai M, Imai M, Kanai T, Tamura T, et al. Small-cell carcinoma of the uterine cervix: a clinicopathologic study of 11 cases. Int J Gynecol Cancer. 2005;15:295–300. https://doi.org/10.1111/j.1525-1438.2005.15219.x.PubMedCrossRef

118.

Turner WA, Gallup DG, Talledo OE, Otken LB, Guthrie TH. Neuroendocrine carcinoma of the uterine cervix complicated by pregnancy: case report and review of the literature. Obstet Gynecol. 1986;67:80S–3S.PubMedCrossRef

119.

van Nagell JR, Donaldson ES, Wood EG, Maruyama Y, Utley J. Small cell cancer of the uterine cervix. Cancer. 1977;40:2243–9.PubMedCrossRef

120.

van Nagell JR, Powell DE, Gallion HH, Elliott DG, Donaldson ES, Carpenter AE, et al. Small cell carcinoma of the uterine cervix. Cancer. 1988;62:1586–93.PubMedCrossRef

121.

Viswanathan AN, Deavers MT, Jhingran A, Ramirez PT, Levenback C, Eifel PJ. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. Gynecol Oncol. 2004;93:27–33. https://doi.org/10.1016/j.ygyno.2003.12.027.PubMedCrossRef

122.

Walker AN, Mills SE, Taylor PT. Cervical neuroendocrine carcinoma: a clinical and light microscopic study of 14 cases. Int J Gynecol Pathol. 1988;7:64–74.PubMedCrossRef

123.

Wang K-L, Wang T-Y, Huang Y-C, Lai JC-Y, Chang T-C, Yen M-S. Human papillomavirus type and clinical manifestation in seven cases of large-cell neuroendocrine cervical carcinoma. J Formos Med Assoc. 2009;108:428–32. https://doi.org/10.1016/S0929-6646(09)60088-7.PubMedCrossRef

124.

Wang K-L, Yang Y-C, Wang T-Y, Chen J-R, Chen T-C, Chen H-S, et al. Neuroendocrine carcinoma of the uterine cervix: a clinicopathologic retrospective study of 31 cases with prognostic implications. J Chemother. 2006;18:209–16. https://doi.org/10.1179/joc.2006.18.2.209.PubMedCrossRef

125.

Wang Y, Mei K, Xiang MF, Li JM, Xie RM. Clinicopathological characteristics and outcome of patients with small cell neuroendocrine carcinoma of the uterine cervix: case series and literature review. Eur J Gynaecol Oncol. 2013;34:307–10.PubMed

126.

Weed JC, Graff AT, Shoup B, Tawfik O. Small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix. J Am Coll Surg. 2003;197:44–51. https://doi.org/10.1016/S1072-7515(03)00120-0.PubMedCrossRef

127.

Wistuba II, Thomas B, Behrens C, Onuki N, Lindberg G, Albores-Saavedra J, Gazdar AF. Molecular abnormalities associated with endocrine tumors of the uterine cervix. Gynecol Oncol. 1999;72:3–9. https://doi.org/10.1006/gyno.1998.5248.PubMedCrossRef

128.

Wu P-Y, Cheng Y-M, New GH, Chou C-Y, Chiang C-T, Tsai H-W, Huang Y-F. Case report: term birth after fertility-sparing treatments for stage IB1 small cell neuroendocrine carcinoma of the cervix. BMC Womens Health. 2017;17:56. https://doi.org/10.1186/s12905-017-0404-0.PubMedPubMedCentralCrossRef

129.

Yin ZM, Yu AJ, Wu MJ, Zhu JQ, Zhang X, Chen JH, et al. Prognostic factors and treatment comparison in small cell neuroendocrine cervical carcinoma. Eur J Gynaecol Oncol. 2014;35:259–63.PubMed

130.

Yoshida Y, Sato K, Katayama K, Yamaguchi A, Imamura Y, Kotsuji F. Atypical metastatic carcinoid of the uterine cervix and review of the literature. J Obstet Gynaecol Res. 2011;37:636–40. https://doi.org/10.1111/j.1447-0756.2010.01402.x.PubMedCrossRef

131.

Yousef I, Siyam F, Layfield L, Freter C, Sowers JR. Cervical neuroendocrine tumor in a young female with lynch syndrome. Neuro Endocrinol Lett. 2014;35:89–94.PubMedPubMedCentral

132.

Yuan L, Jiang H, Lu Y, Guo S-W, Liu X. Prognostic factors of surgically treated early-stage small cell neuroendocrine carcinoma of the cervix. Int J Gynecol Cancer. 2015;25:1315–21. https://doi.org/10.1097/IGC.0000000000000496.PubMedCrossRef

133.

Yun K, Cho NP, Glassford GN. Large cell neuroendocrine carcinoma of the uterine cervix: a report of a case with coexisting cervical intraepithelial neoplasia and human papillomavirus 16. Pathology. 1999;31:158–61.PubMedCrossRef

134.

Zaid T, Burzawa J, Basen-Engquist K, Bodurka DC, Ramondetta LM, Brown J, Frumovitz M. Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: a feasibility study. Gynecol Oncol. 2014;132:149–53. https://doi.org/10.1016/j.ygyno.2013.10.015.PubMedCrossRef

135.

Baggar S, Ouahbi H, Azegrar M, El M'rabet FZ, Arifi S, Mellas N. Carcinome neuroendocrine du col utérin: À propos d’un cas avec revue de la littérature. Pan Afr Med J. 2017;27:82. https://doi.org/10.11604/pamj.2017.27.82.10902.PubMedPubMedCentralCrossRef

136.

Bellefqih S, Khalil J, Mezouri I, Kebdani T, Benjaafar N. Carcinome neuroendocrine à petites cellules du col utérin: À propos de six cas et revue de la littérature. Cancer Radiother. 2014;18:201–7. https://doi.org/10.1016/j.canrad.2014.01.003.PubMedCrossRef

137.

Boruta DM, Schorge JO, Duska LA, Crum CP, Castrillon DH, Sheets EE. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. Gynecol Oncol. 2001;81:82–7. https://doi.org/10.1006/gyno.2000.6118.PubMedCrossRef

138.

Chang TC, Lai CH, Tseng CJ, Hsueh S, Huang KG, Chou HH. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. Cancer. 1998;83:712–8.PubMedCrossRef

139.

Dongol S, Tai Y, Shao Y, Jiang J, Kong B. A retrospective clinicopathological analysis of small-cell carcinoma of the uterine cervix. Mol Clin Oncol. 2014;2:71–5. https://doi.org/10.3892/mco.2013.193.PubMedCrossRef

140.

Frumovitz M, Munsell MF, Burzawa JK, Byers LA, Ramalingam P, Brown J, Coleman RL. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2017;144:46–50. https://doi.org/10.1016/j.ygyno.2016.10.040.PubMedCrossRef

141.

Futagami M, Yokoyama Y, Mizunuma H. Presentation of a patient with pT2bN1M0 small cell carcinoma of the uterine cervix who obtained long-term survival with maintenance chemotherapy, and literature-based discussion. Eur J Gynaecol Oncol. 2011;32:99–102.PubMed

142.

Lee DY, Chong C, Lee M, Kim JW, Park NH, Song YS, Park SY. Prognostic factors in neuroendocrine cervical carcinoma. Obstet Gynecol Sci. 2016;59:116–22. https://doi.org/10.5468/ogs.2016.59.2.116.PubMedPubMedCentralCrossRef

143.

Lewandowski GS, Copeland LJ. A potential role for intensive chemotherapy in the treatment of small cell neuroendocrine tumors of the cervix. Gynecol Oncol. 1993;48:127–31. https://doi.org/10.1006/gyno.1993.1021.PubMedCrossRef

144.

Lyons YA, Frumovitz M, Soliman PT. Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation. Gynecol Oncol Rep. 2014;10:28–9. https://doi.org/10.1016/j.gore.2014.09.003.PubMedPubMedCentralCrossRef

145.

Margolis B, Tergas AI, Chen L, Hou JY, Burke WM, Hu JC, et al. Natural history and outcome of neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2016;141:247–54. https://doi.org/10.1016/j.ygyno.2016.02.008.PubMedPubMedCentralCrossRef

146.

McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, et al. Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease. Gynecol Oncol. 2013;129:135–9. https://doi.org/10.1016/j.ygyno.2013.01.014.PubMedCrossRef

147.

Murakami R, Kou I, Date K, Nakayama H. Advanced composite of large cell neuroendocrine carcinoma and squamous cell carcinoma: a case report of uterine cervical cancer in a virgin woman. Case Rep Obstet Gynecol. 2013;2013:921384. https://doi.org/10.1155/2013/921384.PubMedPubMedCentralCrossRef

148.

Omori M, Hashi A, Kondo T, Tagaya H, Hirata S. Successful neoadjuvant chemotherapy for large cell neuroendocrine carcinoma of the cervix: a case report. Gynecol Oncol Case Rep. 2014;8:4–6. https://doi.org/10.1016/j.gynor.2013.12.001.PubMedCrossRef

149.

Paraghamian SE, Longoria TC, Eskander RN. Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report. Gynecol Oncol Res Pract. 2017;4:3. https://doi.org/10.1186/s40661-017-0038-9.PubMedPubMedCentralCrossRef

150.

Peng P, Ming W, Jiaxin Y, Keng S. Neuroendocrine tumor of the uterine cervix: a clinicopathologic study of 14 cases. Arch Gynecol Obstet. 2012;286:1247–53. https://doi.org/10.1007/s00404-012-2407-2.PubMedCrossRef

151.

Rajkumar S, Iyer R, Culora G, Lane G. Fertility sparing management of large cell neuroendocrine tumour of cervix: a case report & review of literature. Gynecol Oncol Rep. 2016;18:15–7. https://doi.org/10.1016/j.gore.2016.10.002.PubMedPubMedCentralCrossRef

152.

Sheth S, Shende D, Arneja S. Small cell neuroendocrine carcinoma of cervix and leiomyoma between the vagina and rectum. J Obstet Gynaecol. 2015;35:314–5. https://doi.org/10.3109/01443615.2014.940295.PubMedCrossRef

153.

Stecklein SR, Jhingran A, Burzawa J, Ramalingam P, Klopp AH, Eifel PJ, Frumovitz M. Patterns of recurrence and survival in neuroendocrine cervical cancer. Gynecol Oncol. 2016;143:552–7. https://doi.org/10.1016/j.ygyno.2016.09.011.PubMedCrossRefPubMedCentral

154.

Tanimoto H, Hamasaki A, Akimoto Y, Honda H, Takao Y, Okamoto K, et al. A case of large cell neuroendocrine carcinoma (LCNEC) of the uterine cervix successfully treated by postoperative CPT-11+CDDP chemotherapy after non-curative surgery. Gan To Kagaku Ryoho. 2012;39:1439–41.PubMed

155.

Wang PH, Liu YC, Lai CR, Chao HT, Yuan CC, Small YKJ. Cell carcinoma of the cervix: analysis of clinical and pathological findings. Eur J Gynaecol Oncol. 1998;19:189–92.PubMed

156.

Wang Q, Liu Y-H, Xie L, Hu W-J, Liu B-R. Small cell carcinoma of the uterine cervix in pregnancy: a case report and review of the literature. Oncol Lett. 2015;9:91–5. https://doi.org/10.3892/ol.2014.2668.PubMedCrossRef

157.

Wang Z, Wu L, Yao H, Sun Y, Li X, Li B, et al. Clinical analysis of 32 cases with neuroendocrine carcinoma of the uterine cervix in early-stage disease. Zhonghua Fu Chan Ke Za Zhi. 2015;50:198–203.PubMed

158.

Xie S, Song L, Yang F, Tang C, Yang S, He J, Pan X. Enhanced efficacy of adjuvant chemotherapy and radiotherapy in selected cases of surgically resected neuroendocrine carcinoma of the uterine cervix: a retrospective cohort study. Medicine (Baltimore). 2017;96:e6361. https://doi.org/10.1097/MD.0000000000006361.CrossRef

159.

Zivanovic O, Leitao MM, Park KJ, Zhao H, Diaz JP, Konner J, et al. Small cell neuroendocrine carcinoma of the cervix: analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy. Gynecol Oncol. 2009;112(3):590. https://doi.org/10.1016/j.ygyno.2008.11.010.PubMedCrossRef

Title: Neuroendocrine carcinoma of the cervix: a systematic review of the literature
Authors: Clemens B. Tempfer
Iris Tischoff
Askin Dogan
Ziad Hilal
Beate Schultheis
Peter Kern
Günther A. Rezniczek
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4447-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Using hospital registries in Australia to extend data availability on vulval cancer treatment and survival

Is it sufficient to evaluate bone marrow involvement in newly diagnosed lymphomas using 18F-FDG PET/CT and/or routine iliac crest biopsy? A new approach of PET/CT-guided targeted bone marrow biopsy

Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells

Impact of body mass index on surgical outcomes of gastric cancer

MicroRNA-29b-2-5p inhibits cell proliferation by directly targeting Cbl-b in pancreatic ductal adenocarcinoma

A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer